trilinolenin: RN refers to (cis,cis,cis)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
1,2,3-trilinolenoylglycerol : A triglyceride formed by acylation of the three hydroxy groups of glycerol with linolenic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
ID Source | ID |
---|---|
PubMed CID | 5462874 |
CHEBI ID | 75845 |
SCHEMBL ID | 114353 |
MeSH ID | M0265643 |
Synonym |
---|
1,2,3-tri-(9z,12z,15z-octadecatrienoyl)-glycerol |
tg(18:3/18:3/18:3) |
LMGL03010527 |
tg(18:3(9z,12z,15z)/18:3(9z,12z,15z)/18:3(9z,12z,15z)) |
trilinolenin |
glyceryl trilinolenate, >=97% (tlc), liquid |
trilinolenin c18:3 |
propane-1,2,3-triyl (9z,12z,15z,9'z,12'z,15'z,9''z,12''z,15''z)tris-octadeca-9,12,15-trienoate |
14465-68-0 |
2,3-bis[[(9z,12z,15z)-octadeca-9,12,15-trienoyl]oxy]propyl (9z,12z,15z)-octadeca-9,12,15-trienoate |
1,2,3-propanetriyl-9,12,15-octadecatrienoate |
9,12,15-octadecatrienoic acid, 1,2,3-propanetriyl ester |
1,2,3-propanetriyl linolenate |
glyceryl trilinolenate |
unii-oi7s0a9873 |
linolenic acid, 1,2,3-propanetriyl ester |
einecs 238-457-5 |
glycerol trilinolenate |
propane-1,2,3-triyl tris((9z,12z,15z)-octadeca-9,12,15-trienoate) |
oi7s0a9873 , |
1,2,3-trilinolenoylglycerol |
tg[18:3(omega-3)/18:3(omega-3)/18:3(omega-3)] |
triacylglycerol(18:3/18:3/18:3) |
triacylglycerol(54:9) |
1,2,3-tri-(9z,12z,15z-octadecatrienoyl)glycerol |
CHEBI:75845 |
1,2,3-tri-(9z,12z,15z)-octadecatrienoylglycerol |
tag(54:9) |
linolenoyl triglyceride |
tag(18:3/18:3/18:3) |
linolenin, tri- |
vitamin f [who-dd] |
vitamin f glycerinester |
9,12,15-octadecatrienoic acid, 1,1',1''-(1,2,3-propanetriyl) ester, (9z,9'z,9''z,12z,12'z,12''z,15z,15'z,15''z)- |
9,12,15-octadecatrienoic acid, 1,2,3-propanetriyl ester, (all-z)- |
tri-.alpha.-linolenin |
9,12,15-octadecatrienoic acid, 1,2,3-propanetriyl ester, (9z,9'z,9''z,12z,12'z,12''z,15z,15'z,15''z)- |
trilinolenin [inci] |
SCHEMBL114353 |
DTXSID6042654 |
UBEIMDKGOYBUKT-FLIQGJDUSA-N |
J-007993 |
1-a-linolenoyl-2-a-linolenoyl-3-a-linolenoyl-glycerol |
1-(9z,12z,15z-octadeatrienoyl)-2-(9z,12z,15z-octadeatrienoyl)-3-(9z,12z,15z-octadeatrienoyl)-glycerol |
Q27145591 |
tri-9(z),12(z),15(z)-octadecatrienoin, trilinolenin |
tri-9(z),12(z),15(z)-octadecatrienoin |
1, 2, 3-trilinolenoylglycerol |
PD044130 |
tg 18:3_18:3_18:3 |
Excerpt | Reference | Relevance |
---|---|---|
" Trilinolenin (18:3; omega-3) was toxic only after prolonged incubation." | ( Toxicity of polyunsaturated fatty acid esters for human monocyte-macrophages: the anomalous behaviour of cholesteryl linolenate. Carpenter, KL; Hardwick, SJ; Hird, R; Law, NS; Marchant, CE; Mitchinson, MJ; Van Der Veen, C, 1997) | 1.21 |
Excerpt | Reference | Relevance |
---|---|---|
" In a 2-week-long term, daily gavage study, the bioavailability of fish oil and fish oil in Cas-Glu-DGS-50 or Cas-Hylon-25 demonstrated that fish oil and Cas-Glu-DGS-50 LC n-3 PUFA were incorporated into the tissue of the small intestine and colon, whereas Cas-Hylon-25 was resistant to degradation in the small intestine." | ( Site specific delivery of microencapsulated fish oil to the gastrointestinal tract of the rat. Abeywardena, MY; Augustin, MA; Head, RJ; Patten, GS; Sanguansri, L, 2009) | 0.35 |
Class | Description |
---|---|
triacylglycerol 54:9 | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (16.67) | 18.2507 |
2000's | 2 (16.67) | 29.6817 |
2010's | 5 (41.67) | 24.3611 |
2020's | 3 (25.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.22) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |